Catalog No.
Product Name
Application
Product Information
Citations
-
Dopamine Receptor Agonist
Pramipexole is a selective dopamine D2-type receptor agonist that effectively penetrates the blood-brain barrier. It exhibits high affinity with Kis of 2.2 nM for the D2-type receptor, 3.9 nM for D2, 0.5 nM for D3, and 1.3 nM for D4 receptors. This compound is utilized in research related to Parkinson's disease and restless legs syndrome, supporting studies aimed at understanding and treating these neurological disorders. -
D2 Receptor Antagonist
Eticlopride hydrochloride is a selective antagonist of the dopamine D2 receptor, demonstrating high binding affinity for D2, α1-adrenergic, α2-adrenergic, and various serotonin receptors. This compound has KIs of 0.09 nM for D2, 112 nM for α1, 699 nM for α2, 6220 nM for 5HT1, and 830 nM for 5HT2. Eticlopride hydrochloride is primarily utilized in research related to antipsychotic mechanisms and dopamine signaling pathways. -
D1/D5 Dopamine Receptor Agonist
Dihydrexidine hydrochloride is a potent and selective agonist of the D1-like dopamine receptors (D1/D5), exhibiting an IC50 of 10 nM for the D1 receptor. This compound demonstrates significant antiparkinsonian activity, making it valuable in neurological research. Additionally, Dihydrexidine hydrochloride has been shown to stimulate YAP phosphorylation, indicating its potential role in cellular signaling studies. -
Dopamine D2 Receptors Agonist
Lisuride is an orally active agonist of the dopamine D2 receptor, primarily utilized in neurological research. This ergot derivative is valuable for investigating conditions such as Parkinson's disease, migraine disorders, and hyperprolactinemia. Its ability to modulate dopamine activity makes Lisuride a significant compound for studying dopaminergic pathways and associated therapeutic strategies. -
Na+/Ca2+ Channel Blocker
Flunarizine is a potent dual blocker of Na+ and Ca2+ channels, specifically targeting T-type channels. It acts as a D2 dopamine receptor antagonist, exhibiting notable anticonvulsive and antimigraine properties. Additionally, flunarizine demonstrates peripheral vasodilatory effects, making it useful in research related to neurological disorders and vascular function. -
Antipsychotic Drug
Piperacetazine is a phenothiazine antipsychotic that primarily functions as a dopamine receptor antagonist. It has demonstrated inhibitory effects on the transcriptional activity of the PAX3::FOXO1 fusion protein, along with antitumor activity, exhibiting an IC50 of 7.627 μM against PANC-1 cells. This compound is applicable in research related to schizophrenia, pancreatic cancer, and other tumor types, making it a valuable tool for studying both neuropsychiatric disorders and cancer biology. -
Dopamine Receptor Antagonist
Tetrahydroberberine is a potent dopamine D2 receptor antagonist, which modulates dopaminergic signaling pathways. Its biological activity includes potential gastrointestinal benefits, such as enhancing gastric function and alleviating gastric pressure. This compound is of interest in research applications focused on neuropharmacology and gastrointestinal physiology. -
Drd2 Agonist
UNC9995 is a β-arrestin2-biased agonist of the dopamine receptor Drd2. This compound inhibits NLRP3 inflammasome activation by promoting the interaction between β-arrestin2 and NLRP3, thereby preventing neuronal degeneration. Furthermore, UNC9995 activates Drd2/β-arrestin2 signaling, which mitigates the transcription of inflammation-related genes induced by the JAK/STAT3 pathway. Research shows that UNC9995 enhances depressive behavior in mouse models and improves astrocyte dysfunctions, making it a valuable tool for studying neuroinflammatory processes and mood disorders. -
Dopamine D2 Receptor Agonist
MLS1547 is a potent G protein-biased agonist of the dopamine D2 receptor (D2R) with a Ki value of 1.2 μM. It effectively stimulates G protein-mediated signaling pathways, exhibiting an EC50 of 0.37 μM in calcium mobilization assays. Additionally, MLS1547 functions as an antagonist for dopamine-stimulated β-arrestin recruitment to the D2R, demonstrating an IC50 of 9.9 μM. This compound is valuable for investigating D2R signaling mechanisms and exploring therapeutic strategies for disorders associated with dopamine dysregulation. -
Dopamine Receptor Antagonist
Zuclopenthixol is a thioxanthene derivative that functions as a mixed antagonist of dopamine D1 and D2 receptors. This compound has demonstrated antipsychotic properties and is primarily utilized in research related to neuropharmacology and the treatment of schizophrenia. Its ability to modulate dopaminergic signaling makes it a valuable tool for studying dopamine-related disorders and therapeutic interventions. -
Dopamine Receptor Antagonist
Pericyazine is a selective D2-dopamine receptor antagonist primarily utilized in the management of severe anxiety states and psychosis. This first-generation antipsychotic demonstrates key biological activities, including adrenolytic and anticholinergic effects, as well as potential extrapyramidal symptoms. Research applications of pericyazine extend to neuropharmacology, helping to elucidate the role of dopamine in psychiatric disorders. -
Dopamine Receptor Agonist
PD-168077 maleate is a selective agonist targeting the dopamine D4 receptor, exhibiting a Ki value of 9 nM. This compound demonstrates the ability to activate dopamine signaling pathways, making it a valuable tool for research into neuropharmacology and psychiatric disorders. Its targeted mechanism is essential for studying the roles of dopamine receptor subtypes in various biological contexts. -
D2 Receptor Antagonist
(S)-Remoxipride hydrochloride is a selective antagonist of the dopamine D2 receptor, exhibiting an IC50 value of 1.57 μM. This compound is primarily utilized in research related to psychotic disorders, aiding in the exploration of dopamine receptor pathways and their roles in neuropsychiatric conditions. Its specificity for the D2 receptor positions it as a valuable tool for studying schizophrenia and other related disorders. -
Dopamine Receptor Antagonist
D-Tetrahydropalmatine is an isoquinoline alkaloid that functions as a dopamine receptor antagonist, with a preferential affinity for D1 receptors. This compound exhibits significant inhibitory activity against organic cation transporter 1 (OCT1). D-Tetrahydropalmatine is utilized in research focused on neurological disorders and the modulation of dopamine signaling pathways. Its unique properties make it a valuable tool in the exploration of receptor interactions and pharmacological investigations. -
Dopamine D3 Receptor Antagonist
NGB 2904 is a potent and selective antagonist of the dopamine D3 receptor, demonstrating a Ki value of 1.4 nM. This compound exhibits high selectivity for the D3 receptor compared to other targets, including D2, 5-HT2, and α1 receptors, with Kis ranging from 217 to >10,000 nM. NGB 2904 effectively antagonizes Quinpirole-stimulated mitogenesis, making it a valuable tool for research into dopamine-related pathways and potential therapeutic applications in neuropsychiatric disorders. -
D3 Dopamine Receptor Agonist
ML417 is a selective agonist for the D3 dopamine receptor (D3R), demonstrating an EC50 of 38 nM. This compound effectively stimulates D3R-mediated β-arrestin translocation, facilitates G protein signaling, and induces pERK phosphorylation while exhibiting minimal interference with other GPCR pathways. ML417 also offers neuroprotective effects against toxin-induced neurodegeneration of dopaminergic neurons, making it a valuable tool for studying neurodegenerative diseases and dopamine-related disorders. -
DRD2 Antagonist
Propionylpromazine hydrochloride is a dopamine receptor D2 (DRD2) antagonist. This compound exhibits potential in the modulation of dopaminergic signaling, making it relevant for studies related to Parkinson's disease and other disorders associated with dopamine dysregulation. Its ability to inhibit DRD2 may aid in understanding the physiological and pathological roles of dopamine in various neurological contexts. -
Phospholipase D Inhibitor
Halopemide is a potent inhibitor of phospholipase D (PLD), exhibiting IC50 values of 220 nM for human PLD1 and 310 nM for PLD2. In addition to its enzymatic inhibition, Halopemide functions as a dopamine receptor antagonist and exhibits psychotropic properties. This reagent is valuable for research applications exploring PLD-mediated signaling pathways and dopamine receptor interactions in various biological contexts. -
DA Receptor Antagonist
Butyrophenone is a dopamine receptor (DA Receptor) antagonist that plays a significant role in neuropharmacological studies. This compound is primarily utilized in research focused on mental disorders such as schizophrenia and bipolar disorder. Its ability to modulate dopaminergic signaling makes it valuable for investigating the underlying mechanisms of these conditions and potential therapeutic interventions. -
Dopamine Receptor Antagonist
PG01037 dihydrochloride is a potent and selective antagonist of the dopamine D3 receptor, with a dissociation constant (Ki) of 0.7 nM. This compound is valuable in research applications exploring the role of dopamine signaling in various neurological and psychiatric disorders. Its ability to inhibit D3 receptor activity makes it a pivotal tool for investigating potential therapeutic interventions and understanding dopamine-related pathways. -
Dopamine D2 Receptor Antagonist
Domperidone monomaleate is a selective antagonist of the dopamine D2 receptor. This compound exhibits notable antiemetic and prokinetic properties by influencing the chemoreceptor trigger zone and enhancing gastrointestinal motility. It is primarily utilized in research related to gastrointestinal disorders and neuropharmacology. -
Dopamine Receptor Modulator
Neuromedin N is a potent dopamine D2 receptor modulator that enhances agonist binding in rat neostriatal membranes. This compound plays a significant role in the investigation of dopaminergic signaling pathways and their implications in neurobiology. Neuromedin N's ability to influence dopamine receptor activity makes it valuable for research into neuropsychiatric disorders and related therapeutic strategies. -
Antipsychotic Compound
Lenperone is an antipsychotic compound that primarily targets dopamine receptors. It exhibits notable efficacy in alleviating depressive symptoms associated with psychotic disorders. Research applications include studying its effects on neurotransmitter modulation and exploring its potential in psychiatric treatment protocols. -
Dopamine Receptor Antagonist
Fallypride is a potent antagonist of the dopamine D2 and D3 receptors, providing valuable insights into dopaminergic function. As a radiolabeled compound (Fallypride-18F), it serves as an effective positron emission tomography (PET) radiotracer for studying neurological disorders and neuropharmacology. Its application in imaging facilitates the exploration of dopamine-related mechanisms in various psychiatric and neurodegenerative conditions. -
Dopamine Receptor Inhibitor
Clopenthixol is a thiaquinoline compound that acts as an antagonist of D1 and D2 dopamine receptors. It exhibits inhibitory effects comparable to those of phenothiazine antipsychotics, making it valuable in the treatment of schizophrenia and other mental disorders. This compound is primarily utilized in research related to psychiatric conditions and the exploration of dopamine regulation in the central nervous system. -
Dopamine D2 Receptor Antagonist
Sultopride hydrochloride is a selective antagonist of the dopamine D2 receptor, exerting its primary mechanism of action through blocking dopamine signaling. This compound is chiefly utilized in research investigating the role of dopamine in neuropsychiatric disorders and the pharmacological modulation of dopaminergic pathways. Its ability to selectively inhibit D2 receptor activity makes it a valuable tool for exploring dopamine-related biological processes and the development of therapeutic agents. -
Dopamine Receptor Antagonist
Bromopride is a selective, irreversible antagonist of the dopamine D2 receptor, demonstrating significant utility in pharmacological research. This compound effectively crosses the blood-brain barrier, inhibiting the vomiting center and enhancing gastrointestinal motility, thereby exhibiting both antiemetic and prokinetic properties. Bromopride's ability to block dopamine-mediated vomiting reflexes and stimulate gastrointestinal smooth muscle contraction makes it a valuable reagent for investigating digestive system disorders, particularly gastric hypomotility, nausea, and vomiting, without adversely affecting abdominal wall healing in animal models. -
SR-2A/D2DR Inhibitor
Octoclothepin maleate salt is a dual inhibitor of the SR-2A and D2 dopamine receptors. This compound exhibits significant central depressant activity, demonstrated in various observational and instrumental studies using rodent models. Its properties make it a valuable tool in neuropharmacological research, particularly in the study of neuroleptic effects and dopaminergic signaling pathways. -
D4 Receptor Antagonist
Sonepiprazole is a selective D4 dopamine receptor antagonist, exhibiting Ki values of 3.6 nM for the rat D4 receptor and 10.1 nM for the human D4.2 receptor, while showing weaker affinities of 5147 nM and 7430 nM for the rat D2 dopamine and histamine H1 receptors, respectively. This compound demonstrates potential for modulating dopaminergic signaling and is useful in investigating the role of D4 receptors in neurological and psychiatric conditions. Sonepiprazole may serve as a valuable tool for researchers studying the therapeutic implications of dopamine receptor antagonism. -
Antipsychotic Agent
Haloperidol lactate is a potent antipsychotic agent primarily targeting dopamine receptors. It is commonly utilized in the management of acute and chronic schizophrenia, as well as Gilles de la Tourette's syndrome. Additionally, Haloperidol lactate is valuable for research on psychotic disorders, aiding in the exploration of therapeutic pathways and interventions. -
Dopamine Receptor Agonist
Pergolide is an ergot-derived dopamine receptor agonist that primarily targets D1 and D2 dopamine receptors. This compound demonstrates significant biological activity in modulating dopaminergic signaling, making it a valuable tool in the study of Parkinson's disease and related neurological disorders. Pergolide is commonly utilized in research to explore therapeutic mechanisms and potential treatments for motor function impairments associated with dopaminergic deficiencies. -
Stable Isotope
Amisulpride-d5 is a deuterium-labeled derivative of Amisulpride, a selective antagonist of the dopamine D2 and D3 receptors. It exhibits high affinity with Kis of 2.8 nM and 3.2 nM for human D2 and D3 receptors, respectively. This stable isotope is utilized in pharmacokinetic studies, metabolic research, and tracer studies to investigate the pharmacological properties and dynamics of dopamine receptor interactions. -
Dopamine Agonist
ADTN hydrobromide is a long-acting dopamine agonist that targets dopamine receptors to modulate dopaminergic signaling. It has been shown to significantly decrease the behavioral visual threshold in zebrafish models with dopamine depletion, indicating its potential utility in studying dopamine-related pathways and neuropharmacology. This compound is valuable for research applications exploring dopamine receptor functions and related disorders. -
D1R Agonist
(Rac)-Razpipadon is a selective D1 dopamine receptor agonist, demonstrating potent G protein-biased signaling with an EC50 of 5.8 nM in Gs-cAMP assays. This non-catechol compound is valuable for exploring dopamine D1 receptor pathways and studying related neurobiological processes. Its high efficacy makes it suitable for research applications focused on neuropharmacology and the modulation of dopaminergic signaling. -
Stable Isotope
Fluphenazine-d8 is a deuterium-labeled derivative of fluphenazine, functioning primarily as a dopamine receptor antagonist. It effectively inhibits postsynaptic dopamine-2 receptors in key neural pathways, including the mesolimbic, nigrostriatal, and tuberoinfundibular systems. This reagent is valuable in research areas such as psychosis and diabetic peripheral neuropathy, and it has shown potential in studies related to SARS-CoV-2 inhibition. Fluphenazine-d8 serves as a useful tool for elucidating the pharmacodynamics of dopaminergic activity and its downstream effects. -
Dopamine Receptor Antagonist
Fluphenazine hydrochloride functions as a potent dopamine receptor antagonist, primarily targeting postsynaptic dopamine-2 receptors within mesolimbic, nigrostriatal, and tuberoinfundibular pathways. This compound exhibits significant biological activity by blocking neuronal voltage-gated sodium channels, leading to effects on behavior, such as the antagonism of methylphenidate-induced stereotyped gnawing and inhibition of climbing behavior in murine models. Fluphenazine hydrochloride is valuable for research into psychotic disorders and painful peripheral neuropathy related to diabetes, and it has demonstrated potential for inhibition of SARS-CoV-2. -
Dopamine Receptor Antagonist
Fluphenazine dimaleate is a potent dopamine receptor antagonist primarily targeting postsynaptic dopamine-2 receptors in the mesolimbic, nigrostriatal, and tuberoinfundibular pathways. Its ability to antagonize neuronal voltage-gated sodium channels contributes to its effectiveness in modulating dopaminergic activity. Fluphenazine dimaleate is valuable in research addressing psychosis, diabetic neuropathy, and behavioral studies, including the inhibition of Methylphenidate-induced stereotyped behaviors in animal models. Emerging studies also suggest its potential in inhibiting SARS-CoV-2, positioning it as a multifaceted tool in scientific investigation. -
Dopamine Receptor Agonist
Mergocriptine is a dopamine receptor agonist that has been identified as a ligand for the SARS-CoV-2 main protease (Mpro). This compound plays a significant role in modulating ambulatory activity and may be utilized in research focused on neurological disorders and viral pathogenesis. Its dual action positions it as a valuable tool in studying dopamine-related pathways and potential antiviral mechanisms. -
A2AR-D2R Heteromer Ligand
Heterobivalent ligand-1 is a potent heterobivalent ligand targeting the Adenosine A2A-dopamine D2 receptor heteromer, exhibiting binding affinities of 2.1 nM for A2AR and 0.13 nM for D2R. This compound is valuable for studying receptor heteromerization and signal transduction in neurological research. Its unique design enables exploration of the functional interplay between these receptors in various biological contexts. -
D3R PAM-Antagonist
MLS6357, a D3 dopamine receptor (D3R)-selective positive allosteric modulator and antagonist, demonstrates significant antagonist activity in D3R-mediated assays, including BRET-based β-arrestin recruitment and Go-BRET assays, with IC50 values of 13 μM, 14 μM, and 17 μM respectively. It shows selectivity for D3R, with no notable activity on other dopamine receptor subtypes (D1R, D2R, D4R, D5R) at concentrations above 100 μM. MLS6357 serves as a valuable tool for investigating neuropsychiatric disorders, particularly in the context of substance use disorders. -
DRD4 Antagonist
PD 168568 is a potent and orally active antagonist of the dopamine receptor D4 (DRD4), featuring an isoindolinone structure. It demonstrates strong selectivity for the D4 receptor over D2 and D3 receptors, with Ki values of 8.8 nM, 1842 nM, and 2682 nM, respectively. This compound is valuable for research applications focusing on glioblastoma (GBM), providing insights into the role of DRD4 in tumor biology. -
D3R Antagonist
PF-04363467 is a selective antagonist of the dopamine D3 receptor (D3R). It demonstrates dose-dependent modulation of the electroencephalogram (EEG) profile in freely moving rats, highlighting its potential to influence neural activity. This compound effectively reduces opioid drug-seeking behavior while minimizing undesired side effects associated with D2 receptor antagonism. PF-04363467 is valuable for research into addiction, cognitive disorders, and mental illness. -
Dopamine Autoreceptor Agonist
PD 128483 is a selective agonist of the dopamine autoreceptor, primarily engaging the D2 receptor subtype. This compound is instrumental in research related to neurological diseases, facilitating studies on dopamine signaling and its implications in disorders such as schizophrenia and Parkinson’s disease. Its ability to modulate dopamine release provides valuable insights into neuropharmacology and therapeutic interventions. -
Haloperidol Analogue
UCSF34 is a Haloperidol analogue that selectively binds to the human D2L receptor, exhibiting an estimated pKi of 7.49. This compound is significant for its potential applications in schizophrenia research, facilitating the investigation of dopamine receptor modulation and related therapeutic strategies. -
Dopamine Receptor Antagonist
Seridopidine is a potent dopamine receptor antagonist that primarily targets D2 and D3 receptors. It exhibits significant antipsychotic activity, making it valuable for research in neurological and psychiatric disorders. This compound is useful in studies investigating the roles of dopamine in the central nervous system, particularly in understanding mechanisms underlying schizophrenia and related conditions. -
Dopamine D2 Receptor Agonist
U 101958 is a potent full agonist of the dopamine D4 receptor, exhibiting a pEC50 of 8.7 in HEK293 cells expressing the D4 receptor. This compound demonstrates significant biological activity and is valuable for research in neuropharmacology, particularly in studies examining the role of dopamine signaling in psychiatric disorders. Its selectivity for the D4 receptor can aid in the exploration of D4-mediated effects in various biological systems. -
Dopamine D1 Receptor PAM
LY3154885 is an orally active positive allosteric modulator (PAM) targeting the dopamine D1 receptor. This compound enhances receptor activity, facilitating increased dopaminergic signaling. Its favorable drug-drug interaction profile makes it a valuable tool for research into dopamine-related pathways and potential therapeutic applications in neuropsychiatric disorders. -
Dopamine Receptor
Quinagolide is a non-ergot dopamine D(2) receptor agonist that enhances dopamine activity. It is primarily utilized in the modulation of endocrine function, particularly in the suppression of hyperprolactinemia and its associated clinical symptoms. Quinagolide's significant biological activity makes it a valuable reagent for research in endocrine disorders and drug development, facilitating the study of dopamine's role in various physiological processes. -
D3R Ligand
D3R ligand 1 is a potent and selective antagonist targeting the dopamine receptor D3R, with a Ki value of 66 nM. Utilizing a THPB template, this compound effectively inhibits both G-protein- and β-arrestin-mediated signaling pathways. D3R ligand 1 is valuable for researchers investigating dopamine receptor signaling and its implications in neuropharmacology. -
D1 Receptor Agonist
A-77636 is a potent and selective orally active agonist of the dopamine D1 receptor, demonstrating a pEC50 of 8.13 and an EC50 of 1.1 nM. It exhibits a high affinity for the dopamine D1 receptor with a pKi value of 7.40 ± 0.09 (Ki = 39.8 nM). Due to its pharmacological profile, A-77636 is primarily utilized in research related to Parkinson's disease and other dopamine-related disorders.
